Ziopharm concludes enrollment in IL-12 & nivolumab combination trial
Category: #health  By Mateen Dalal  Date: 2019-06-27
  • share
  • Twitter
  • Facebook
  • LinkedIn

Ziopharm concludes enrollment in IL-12 & nivolumab combination trial

Controlled IL-12 platform from Ziopharm is an investigational gene therapy designed to control and induce human interleukin 12 production

Ziopharm Oncology Inc, a company that focuses on developing cell therapies and immune-oncology gene, recently announced that they have completed enrolling for third cohort of Phase 1 clinical study to evaluate Controlled IL-12 combined with the PD-1 inhibitor OPDIVO (nivolumab) to treat progressive or recurrent glioblastoma multiforme (rGBM) in adult subjects.

Investigators who will conduct this multi-central trial at the University of Texas MD Anderson Cancer in Houston, Brigham and Women’s Hospital in Boston and Northwestern university in Chicago, have expressed their interest in expanding the study. Based on the final agreement done by the Data and Safety Monitoring Board, the company expects to enroll more patients for the highest dosing level.

Ziopharm’s Chief Executive, Laurence Cooper M.D., Ph.D., said that the company has completed the enrollment of the escalated dose: Ad-RTS-hIL-12+ veledimex along with nivolumab and further explored the potential for the expansion of this combination trial which can enhance their clinical experience.

There is a clear enthusiasm to combine PD-1 inhibitors with IL-12 in the ongoing study and the company is looking forward to starting a phase 2 trial that includes Ad-RTS-Hil-12 + veledimex as well as cemiplimab in the future, Cooper informed.

Citing reliable sources, the Controlled IL-12 platform of Ziopharm is reportedly an investigational gene therapy that is designed to specifically control and induce the human interleukin 12 production, the immune system’s master-regulator. Set in the rGBM, the company has reportedly leveraged anti-tumor effects as monotherapy for Controlled IL-12 with the combination of PD-1 inhibitors.

Apparently, there was a report previously that had a data of patients suffering from serial biopsies with rGBM, which showed that Controlled IL-12 results in upregulation of PD-1 expression and sustained influx of T cells, all of which provides an intriguing rationale for the combination.

Seemingly, it is anticipated that Ziopharm shall report more data from the combination trial at medical meetings this year and into the next.

 

Source Credits- https://ir.ziopharm.com/news-releases/news-release-details/ziopharm-oncology-completes-enrollment-controlled-il-12-plus

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
By Mateen Dalal

Air France–KLM S.A., one of the leading global air transport players, has reportedly made a proposal to invest in Malaysia Airlines and gain around 49 percent stake. Japan Airlines (JAL) is also looking to acquire a 25 percent stake in Mal...

Accenture opens innovation center in South Beach Road office
Accenture opens innovation center in South Beach Road office
By Mateen Dalal

Accenture, an Irish multinational professional services company, has recently opened a global innovation center within the Accenture’s office at South Beach Road, which is supported by EDB (Economic Development Board) in Singapore. It will pro...

Verrica unveils positive data from VP-102 study in molluscum treatment
Verrica unveils positive data from VP-102 study in molluscum treatment
By Mateen Dalal

Findings from the study are being produced at the 17th Annual Winter Clinical Dermatology Conference in Kohala Coast The data indicated a considerable increase in the percentage of patients with lesion clearance in VP-102 group Verrica Pharmaceu...